glp 1 death rate GLP-1s may reduce mortality for people with sickle cell disease glp-1 colorectal cancer death risk

I thought you said in red blood cells

Nutrition and metabolic insights , 9 , NMI-S39764

"For someone with type 2 diabetes or significant obesity, the cardiovascular, kidney and metabolic benefits [of these medications] are large and well-established, and stopping abruptly carries its own risks, so any change should be a conversation with your prescriber," he said

Two major clinical trials are the basis for most of what's known about these medications' weight-management effects: STEP 1 (68-week randomized study, adults without diabetes): semaglutide 2.4 mg produced an average loss of roughly 15% of body weight, versus about 2.4% with placebo, alongside a reduced-calorie diet and increased physical activity

EL CONSUMO DE STE PRODUCTO ES RESPONSABILIDAD DE QUIEN LO RECOMIENDA Y DE QUIEN LO USA.